To the full analysis
CytomX Therapeutics stock: growth
CTMXCytomX Therapeutics reported $76.2M in revenue for fiscal 2025, down 44.8% on the prior year, up 7.2% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
44.9%
per year from 2013 to 2025, per share −4%
Earnings (Annual rate)
no data
Free cash flow (Annual rate)
no data
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2013 | |
|---|---|---|---|
| Revenue | 2.2% | 25.7% | 44.9% |
| Revenue per share | −17.9% | 9.8% | −4.0% |
| Earnings | no data | no data | no data |
| Earnings per share | no data | no data | no data |
| Free cash flow | no data | no data | no data |
| Free cash flow per share | no data | no data | no data |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2013 | $888K | −$15.14M | −$8.74M |
| 2014 | $5.08M | −$30.31M | $30.14M |
| 2015 | $7.71M | −$35.37M | −$29.01M |
| 2016 | $15.04M | −$58.9M | −$4.21M |
| 2017 | $71.62M | −$43.1M | $168.81M |
| 2018 | $59.5M | −$84.6M | −$79.31M |
| 2019 | $57.49M | −$102.24M | −$143.98M |
| 2020 | $68.43M | −$64.82M | $2.95M |
| 2021 | $37.31M | −$115.87M | −$120.64M |
| 2022 | $53.16M | −$99.32M | −$112.53M |
| 2023 | $101.21M | −$569K | −$56.88M |
| 2024 | $138.1M | $31.87M | −$86.54M |
| 2025 | $76.2M | −$17.37M | −$75.81M |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 20 Mar 2026)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.